Launch of Two new Platforms for Microplate Analysis Expands Reader Portfolio
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Molecular Devices, Inc., has announced the launch of two new multi-mode detection platforms that expand its portfolio of microplate readers, enabling the company to meet all combinations of customer needs now and into the future.
Both products will be showcased at Miptec 2010, Switzerland, September 20-24, as well as several other 2010 shows including Het, Scanlab, Biotechnica, SBS China, Society for Neuroscience, and American Society for Cell Biology.
Molecular Device claims that the SpectraMax® Paradigm® Platform is the only user-upgradeable multi-mode reader on the market today and is ideal for drug discovery research, including high-throughput screening. The FilterMax™ F3 and F5 Series Readers deliver assay performance compared to similarly priced readers and are developed for a wide range of life science research applications. Both platforms were developed in response to requests from existing customers, and both are commercially available with shipping to begin in early October.
“With these two new platforms, we now have an ideal microplate reader for any combination of application, detection, and budget needs,” said Mark Verheyden, President of Molecular Devices. “We’ve carefully expanded our portfolio to ensure that we will be able to meet our customers’ needs across ever-evolving research environments. By adding the SpectraMax Paradigm and FilterMax™ F Series Platforms to our existing lines of readers, we now offer the most comprehensive line of microplate readers on the market today.”
The new patent-pending SpectraMax Paradigm Platform is the only multi-mode detection platform on the market that allows users to upgrade the functionality of their instrument directly-no service call, no factory shipment. Upgrading is as easy as selecting from over 20 mix-and-match detection cartridges and inserting them into one or more of 12 instrument slots. A single cartridge can be changed in less than 2 minutes-the instrument can be fully reconfigured in 10 to 20 minutes. This unmatched flexibility provides a platform that can easily be adapted to meet constantly evolving application needs and ever advancing detection technologies while accommodating most budgets.
The new, patented FilterMax F Series Platform can deliver a combination of value, performance, and sensitivity, putting high-performance multi-detection capabilities into the hands of any life science researcher. This filter-based platform delivers assay performance across a broad range of life science applications, and currently offers two models: the F3 with absorbance, fluorescence, and luminescence detection modes and the F5 with those same modes plus fluorescence polarization and time resolved fluorescence modes.
Both products will be showcased at Miptec 2010, Switzerland, September 20-24, as well as several other 2010 shows including Het, Scanlab, Biotechnica, SBS China, Society for Neuroscience, and American Society for Cell Biology.
Molecular Device claims that the SpectraMax® Paradigm® Platform is the only user-upgradeable multi-mode reader on the market today and is ideal for drug discovery research, including high-throughput screening. The FilterMax™ F3 and F5 Series Readers deliver assay performance compared to similarly priced readers and are developed for a wide range of life science research applications. Both platforms were developed in response to requests from existing customers, and both are commercially available with shipping to begin in early October.
“With these two new platforms, we now have an ideal microplate reader for any combination of application, detection, and budget needs,” said Mark Verheyden, President of Molecular Devices. “We’ve carefully expanded our portfolio to ensure that we will be able to meet our customers’ needs across ever-evolving research environments. By adding the SpectraMax Paradigm and FilterMax™ F Series Platforms to our existing lines of readers, we now offer the most comprehensive line of microplate readers on the market today.”
The new patent-pending SpectraMax Paradigm Platform is the only multi-mode detection platform on the market that allows users to upgrade the functionality of their instrument directly-no service call, no factory shipment. Upgrading is as easy as selecting from over 20 mix-and-match detection cartridges and inserting them into one or more of 12 instrument slots. A single cartridge can be changed in less than 2 minutes-the instrument can be fully reconfigured in 10 to 20 minutes. This unmatched flexibility provides a platform that can easily be adapted to meet constantly evolving application needs and ever advancing detection technologies while accommodating most budgets.
The new, patented FilterMax F Series Platform can deliver a combination of value, performance, and sensitivity, putting high-performance multi-detection capabilities into the hands of any life science researcher. This filter-based platform delivers assay performance across a broad range of life science applications, and currently offers two models: the F3 with absorbance, fluorescence, and luminescence detection modes and the F5 with those same modes plus fluorescence polarization and time resolved fluorescence modes.
